Nektar Therapeutics (MEX:NKTR) Inventories, Finished Goods: MXN0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NKTR Nektar Therapeutics MEX:NKTR
47 GF Score
Price MXN1,584.15
GF Value MXN131.04
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Inventories, Finished Goods?

Nektar Therapeutics MEX:NKTR 47 Inventories, Finished Goods is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 47/100 and a GF Value™ of MXN131.04. The stock has 5 warning signs investors should review.

Nektar Therapeutics's annual finished goods declined from Dec. 2023 (MXN23 Mil) to Dec. 2024 (MXN0 Mil) but then stayed the same from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN0 Mil).

Nektar Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Inventories, Finished Goods Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.55 114.60 23.09 0.00 0.00

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:NKTR
47GF Score
Nektar Therapeutics MEX:NKTR
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN0 Mil mean?
Nektar Therapeutics (MEX:NKTR) has a Inventories, Finished Goods of MXN0 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Inventories, Finished Goods too high?
Nektar Therapeutics' current Inventories, Finished Goods is MXN0 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Inventories, Finished Goods compare to OCUL and PVLA?
Nektar Therapeutics' Inventories, Finished Goods of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Inventories, Finished Goods is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Inventories, Finished Goods of MXN0 Mil. The stock's GF Value™ is MXN131.04, compared to a current price of MXN1,584.15 — trading 1108.9% above its estimated fair value. The current Inventories, Finished Goods is MXN0 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Inventories, Finished Goods is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1108.9% above its estimated GF Value™ of MXN131.04.

Key valuation signals for MEX:NKTR:

  • Inventories, Finished Goods: MXN0 Mil
  • GF Value™: MXN131.04 vs. price of MXN1,584.15 (1108.9% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for MEX:NKTR

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN131.04
GF Value